Rare Lung Disease and COPD Research Group

The Rare Lung Disease and COPD Research Group at MUSC is dedicated to advancing the early detection, accurate diagnosis, and effective treatment of rare lung conditions. Led by Charlie Strange, M.D., professor in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, the team focuses on COPD and various rare lung diseases. Dr. Strange, an expert in alpha-1 antitrypsin deficiency and genetic lung disorders, oversees a robust clinical trials program targeting COPD and airway diseases. Current studies investigate bronchoscopic therapies, computed tomography (CT) lung and airway analysis, and disease exacerbations.

Lymphangioleiomyomatosis (LAM) Research

Lymphangioleiomyomatosis (LAM) is a rare, progressive disease that leads to the destruction of lung tissue, predominantly affecting women, particularly during childbearing years. At MUSC, we manage over 40 LAM patients and are actively involved in LAM research studies to better understand and treat this condition.

Lung Health and COPD Research

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease characterized by obstructed airflow, leading to symptoms such as difficulty breathing, chronic cough, excess mucus production, and wheezing. At MUSC, we conduct a variety of research initiatives focused on COPD, exploring new devices, pharmacological treatments, and behavioral interventions.

Alpha-1 Antitrypsin Deficiency (AATD) Research

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder that can cause lung and liver diseases, with potential complications such as COPD, cirrhosis, neonatal jaundice, and panniculitis. AATD is caused by mutations in the SERPINA1 gene, leading to low blood levels of the protective protein alpha-1 antitrypsin (A1AT). MUSC hosts numerous AATD research studies, and interested participants can contact our team for more information.

Alpha-1, COPD, and LAM Research Team Leadership